Pharmaceutical firms sitting on huge cash pile

Published: 2013-03-26 06:59:00

Updated: 2013-03-26 06:59:00

Korean drug makers remain reluctant to invest. Instead, they are choosing to hold record amounts of cash reserves against the continued uncertain economic outlook and government’s drug related policies, which analysts say will weaken their growth potential.

The cash reserve ratio for all 55 li...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK